Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10108	Companies
207148	Keywords
137285	Articles
109793	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 03/24/2025 at 17:45, 1 year ago

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
Newron Pharmaceuticals S.p.A. proposes Chris Martin, ex-CEO of ADC Therapeutics, as Independent Chairman succeeding Dr. Köstlin after 12 years. Martin an experienced biopharma leader

Chairman Biopharma Newron Pharmaceuticals Chris Martin ADC Therapeutics
BRIEF

published on 01/09/2025 at 07:05, 1 year 2 months ago

Newron and Myung In Pharm License Agreement for Evenamide in South Korea

Phase III Trial CNS Therapies Evenamide Schizophrenia Treatment License Agreement
BRIEF

published on 01/09/2025 at 07:05, 1 year 2 months ago

Accord de licence entre Newron et Myung In Pharm pour l'Evenamide en Corée du Sud

Evenamide Traitement De La Schizophrénie Contrat De Licence Essai De Phase III Thérapies Du Système Nerveux Central
PRESS RELEASE

published on 01/09/2025 at 07:00, 1 year 2 months ago

Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. and Myung In Pharm enter license agreement for evenamide in South Korea, aiming to develop innovative treatment option for schizophrenia patients

Newron Pharmaceuticals Evenamide License Agreement South Korea Myung In Pharm
BRIEF

published on 12/13/2024 at 07:05, 1 year 3 months ago

Newron and EA Pharma Sign License Agreement for Evenamide in Asia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment License Agreement EA Pharma
BRIEF

published on 12/13/2024 at 07:05, 1 year 3 months ago

Newron et EA Pharma signent un accord de licence pour Evenamide en Asie

Evenamide Traitement De La Schizophrénie Contrat De Licence Newron Pharmaceutique EA Pharma
PRESS RELEASE

published on 12/13/2024 at 07:00, 1 year 3 months ago

Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Newron Pharmaceuticals S.p.A. and EA Pharma (a subsidiary of Eisai Co., Ltd.) have signed a license agreement for evenamide in Japan and other Asian territories, aiming to address unmet medical needs in patients with schizophrenia

Schizophrenia Newron Pharmaceuticals Evenamide License Agreement EA Pharma
BRIEF

published on 09/19/2024 at 07:05, 1 year 6 months ago

Newron Pharmaceuticals Presents H1 2024 Results and Business Update

Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
BRIEF

published on 09/19/2024 at 07:05, 1 year 6 months ago

Newron Pharmaceuticals présente ses résultats du premier semestre 2024 et son point sur ses activités

Essais Cliniques Evenamide Traitement De La Schizophrénie Premier Semestre 2024 Newron Pharmaceutique
PRESS RELEASE

published on 09/19/2024 at 07:00, 1 year 6 months ago

Newron presents H1 2024 results and provides business update
Newron Pharmaceuticals presents H1 2024 financial results and operational highlights, focusing on evenamide studies for schizophrenia treatment and corporate developments

Financial Results Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024

Accesswire

Published on 03/28/2026 at 01:00, 8 hours 46 minutes ago

Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 8 hours 51 minutes ago

Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 00:50, 8 hours 56 minutes ago

"Rise" Selected as NASA Artemis II Moon Mascot
Published on 03/27/2026 at 22:45, 11 hours 1 minute ago

Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:30, 11 hours 16 minutes ago

Usha Resources Completes Extended Induced Polarization Survey at the Southern Arm Property

View all ACCESSWIRE

EQS Group

Published on 03/28/2026 at 08:56, 49 minutes ago

Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 8 hours 4 minutes ago

EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 11 hours 47 minutes ago

Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 21:58, 11 hours 47 minutes ago

Kaufman & Broad SA: Mise à disposition du Document d'Enregistrement Universel 2025
Published on 03/27/2026 at 20:08, 13 hours 38 minutes ago

EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria

Les Echos

Published on 03/28/2026 at 07:00, 2 hours 46 minutes ago

Groupe DLSI - Résultat 2025
Published on 03/27/2026 at 19:06, 14 hours 39 minutes ago

Mersen : Déclaration des transactions sur actions propres
Published on 03/27/2026 at 19:06, 14 hours 40 minutes ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 14 hours 54 minutes ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:52, 14 hours 54 minutes ago

Crédit Agricole CIB annonce la publication de son Document d’enregistrement universel 2025

View all LES ECHOS COMFI WIRE